Researchers at Swinburne University of Technology have discovered that sulforaphane, a natural compound found in broccoli, can potentially treat Friedreich ataxia, a rare and incurable genetic nervous system disorder affecting approximately 200 Australians. Published in Antioxidants and Redox Signaling on February 22, 2026, the preclinical study demonstrates that sulforaphane raises levels of frataxin, the deficient protein linked to the disease, while mitigating cellular stress, inflammation, and nerve cell damage. Lead author Associate Professor Faith Kwa emphasizes the critical nature of these findings because children make up the majority of patients afflicted with this devastating condition, yet currently lack approved targeted treatments. Sulforaphane targets the underlying cause of the disease while offering an affordable and accessible therapeutic option worldwide, paving the way toward better quality of life and long-term survival for young patients. The research highlights the promising therapeutic profile of sulforaphane, which already boasts an established safety record across both children and adults in its commercially available pure and bioactive forms. This established safety margin means that successful clinical trials could drastically accelerate the rollout process and quickly translate laboratory breakthroughs into real-world patient impact. Securing financial backing and public awareness remains the primary hurdle for the research team due to the extreme rarity of Friedreich ataxia. The investigators are actively seeking funding to launch clinical trials, aiming to validate the preclinical outcomes and establish definitive proof of sulforaphane's positive clinical impact on human patients suffering from this debilitating neurological condition.
